

New Test Announcement



CA 27.29

Effective 9/2/2015, St. Luke's Laboratory will provide "in house" testing for CA 27.29. St. Luke's laboratory is committed to a Lean, automated system, providing state of the art instrumentation and test methodologies. Testing was previously performed as a "send out" test. Turnaround times will be enhanced.

The need to re-baseline patients will not be necessary. Send out testing was performed on a Siemens Centaur and in house testing will be performed on a Siemens Centaur utilizing the same assay.

Measurement of CA 27.29 can aid in monitoring patients previously treated for Stage II or Stage III breast cancer. Serial testing for CA 27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment.

St. Luke's Reference Range:

0.00 – 38.0 U/mL

If you have questions, please contact Kristin Baer, M.D. 218-249-5751, Chemistry Medical Director or Amber LaMourea, MT (ASCP) 218-249-5024, Immunochemistry Technical Specialist.

See St. Luke's Laboratory Services Web page containing New Test Announcements:

<http://www.slhduluth.com/hospital/laboratory-services/>